

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification <sup>7</sup> :</b> <b>A61K</b>	<b>A2</b>	<b>(11) International Publication Number:</b> <b>WO 00/06086</b> <b>(43) International Publication Date:</b> 10 February 2000 (10.02.00)
<b>(21) International Application Number:</b> PCT/US99/17178 <b>(22) International Filing Date:</b> 29 July 1999 (29.07.99) <b>(30) Priority Data:</b> 09/127,651 31 July 1998 (31.07.98) US <b>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application</b> US 09/127,651 (CIP) Filed on 31 July 1998 (31.07.98) <b>(71) Applicant (for all designated States except US):</b> THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK [US/US]; West 116th Street and Broadway, New York, NY 10027 (US). <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> WINCHESTER, Robert, J. [US/US]; 60 East End Avenue, New York, NY 10028 (US). SEKI, Tetsunori [JP/US]; Apartment #411, 595 Main Street, Roosevelt Island, NY 10044 (US). GULKO, Percio, Saltz [BR/US]; Apartment #6H, 3220 Netherland Avenue, Riverdale, NY 10463 (US).		<b>(74) Agent:</b> WHITE, John, P.; Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY 10036 (US). <b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>Without international search report and to be republished upon receipt of that report.</i>
<b>(54) Title:</b> USE OF INHIBITORS OF THE ACTIVATION OF CXCR4 RECEPTOR BY SDF-1 IN TREATING RHEUMATOID ARTHRITIS		
<b>(57) Abstract</b> <p>This invention provides a method for treating rheumatoid arthritis or other forms of inflammatory arthritis which comprises administering to a subject an amount of an agent effective to inhibit the activation of the CXCR4 receptor by SDF-1. This invention further provides a composition for treating rheumatoid arthritis comprising an effective amount of an agent capable of inhibiting the activation of the CXCR4 receptor by SDF-1 and a pharmaceutically acceptable carrier. This invention also provides a method for determining whether an agent is capable of inhibiting the activation of the CXCR4 receptor by SDF-1 comprising: (a) contacting cells expressing the CXCR4 receptor in the presence of SDF-1 with the agent under condition permitting activation of the CXCR4 receptor by SDF-1 if the agent is absent; and (b) determining whether the amount of activation of the CXCR4 receptor by SDF-1 is decreased in the presence of the agent relative to the amount of activation in its absence, such a decrease indicating that the agent is capable of inhibiting the activation of the CXCR4 receptor by SDF-1. Finally, this invention provides agents identified by such a method.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

5                   **USE OF INHIBITORS OF THE ACTIVATION OF CXCR4**  
                  **RECEPTOR BY SDF-1 IN TREATING RHEUMATOID ARTHRITIS**

10       This application claims priority of U.S. Serial No.  
09/127,651, filed July 31, 1998, the content of which is  
hereby incorporated by reference. Throughout this  
15       application various references are referred to by arabic  
numbers within parenthesis. Disclosures of these  
publications in their entireties are hereby incorporated by  
reference into this application to more fully describe the  
state of the art to which this invention pertains.

15                   **Background of the invention**

20       The architecture, cellular composition and state of  
cellular activation of the synovial membrane in rheumatoid  
arthritis have been well described(1,2), but fundamental  
questions still remain unanswered regarding the precise  
molecular nature and biologic significance of these  
inflammatory changes. The intimal synovial lining layer  
that is extensively altered in synovitis synovium through  
25       hyperplasia and infiltration is formed by the interaction  
of two distinct cell types: intimal synoviocytes derived  
from the fibroblastoid lineage and intercalated,  
hemopoietically-derived, monocytoïd lineage cells(3-5).  
During histogenesis of the normal joint the lining cell  
30       apparently provides both guidance clues and receptor  
interactions to the specialized synovial monocytoïd cells  
that result in its incorporation into the lining layer(1).  
Together, the cells comprising the intimal layer carry out  
a number of functions responsible for the integrity and  
35       sustenance of the joint.

40       The form and function of the intimal synoviocyte apparently  
distinguishes them from fibroblastoid cells found deeper in  
the synovium, although relatively little is known about the  
differences between these members of the fibroblastoid  
lineage(6). Several genes have been identified that are

-2-

selectively expressed in the normal intimal, but not subintimal synoviocytes including vascular cell adhesion molecule 1 (VCAM-1) (7), uridine diphosphoglucose dehydrogenase (UDPGD) and decay accelerating factor (DAF) (6). In chronic synovitis immunopathologic studies have shown that the fibroblastoid intimal synoviocytes respond to the events by proliferating and altering their pattern of gene expression to include expression of a variety of molecules that range from MHC class II structures, through cytokines to enzymes that directly participate in the destructive remodelling of joint tissues (1,8-13). In parallel, some of the fibroblasts in subintimal locations similarly express MHC class II and VCAM-1 (6,13). However, the performance of more analytic studies of synoviocyte cell biology has been constrained because there is no basement membrane that delimits intimal synoviocytes from the subintimal fibroblastoid cells in either normal or inflamed joint tissues, and the purification and separate culture of these two potentially distinct lineages has been difficult, if not impossible.

For many years it has been recognized that long term cultures of fibroblastoid cells obtained from synovial tissue of individuals with rheumatoid arthritis and marked degrees of intimal hyperplasia continue to exhibit several phenotypes that together are characterized by varying degrees of striking 'stellate' or 'dendritic' morphology, enhanced growth, increased glucose consumption, altered adherence behavior, constitutive overproduction of metalloproteinases and the elaboration of proinflammatory cytokines (13-16). The distinctive but not entirely uniform phenotype of rheumatoid synoviocytes is not found in similarly cultured synoviocytes obtained from osteoarthritis synovia that lack lining cell hyperplasia and any inflammatory cell infiltration (16). The occurrence of this distinctive phenotype has been shown to be characteristic of, but not unique to, cell lines

-3-

established from rheumatoid arthritis synovia, as it is also demonstrable in cultures initiated from a number of different entities characterized by chronic inflammation, including osteoarthritis synovia with considerable degrees of inflammation(16). These cell lines have been used to gain a series of interesting insights into the biology of joint inflammation (15-22), although the origin of the cells in culture is somewhat uncertain and at least at the time of initiation includes hyperplastic intimal synoviocytes, subintimal synoviocytes, other fibroblastoid cells as well as non mesenchymal cells that do not survive after three passages. We and others have postulated that the distinctive changes in synoviocyte phenotype observed in these cell lines mirror certain similar events occurring in the inflamed synovium itself(14,15,23-25).

Finding additional genes that may be selectively expressed in the cultured synoviocyte obtained from inflammatory synovitis would likely provide further insight into the origin of the synoviocytes comprising the cultures, the biology of the intimal synoviocyte and the alterations that this cell and other synovial fibroblasts undergo in synovitis. To further this gene discovery process, a general approach was adopted based on the construction of representational difference libraries(26,27) that had been used to clone the differences between two complex genomes. It involves a cloning procedure with PCR amplification of cDNA to generate simplified representations of the expressed genes followed by a modified subtractive step and subsequent screening to facilitate the gene identification.

By identification of these genes, it is discovered that SDF-1 is expressed on the synoviocytes which can activate the CXCP4 receptors on lymphocytes and monocytes, either causing them to enter the joint and initiate inflammation through a chemokine effect, or activate these cells that have entered the joint to enhance inflammation.

Summary of the Invention

5 This invention provides a method for treating rheumatoid arthritis or other forms of inflammatory arthritis which comprises administering to a subject an amount of an agent effective to inhibit the activation of the CXCR4 receptor by SDF-1.

10 This invention further provides a composition for treating rheumatoid arthritis comprising an effective amount of an agent capable of inhibiting the activation of the CXCR4 receptor by SDF-1 and a pharmaceutically acceptable carrier.

15 This invention also provides a method for determining whether an agent is capable of inhibiting the activation of a CXCR4 receptor by SDF-1 comprising: (a) contacting cells expressing the CXCR4 receptor in the presence of SDF-1 with the agent under conditions permitting activation of the  
20 CXCR4 receptor by SDF-1 if the agent is absent; and (b) determining whether activation of the CXCR4 receptor by SDF-1 is decreased in the presence of the agent relative to the amount of activation in its absence, such a decrease in the amount of activation indicating that the agent is  
25 capable of inhibiting the activation of the CXCR4 receptor by SDF-1. Finally, this invention provides agents identified by the such a method.

5

15

25

35

-6-

cultured rheumatoid arthritis synoviocytes,  
and the second lane is RNA from cultured  
osteoarthritis synoviocytes.



Detailed Description of the Invention

Throughout this application, reference to specific nucleotides are to nucleotides present on the coding strand of the nucleic acid. The following standard abbreviations are used throughout the specification to indicate specific nucleotides:

	C=cytosine	A=adenosine
10	T=thymidine	G=guanosine

This invention provides a method for treating rheumatoid arthritis or other forms of inflammatory arthritis which comprises administering to a subject suffering from such a condition an amount of an agent effective to inhibit the activation of a CXCR4 receptor by SDF-1, particularly the human CXCR4 receptor. Diseases which represent other forms of inflammatory arthritis are known in the art, and include, but are not limited to, psoriatic arthritis and inflammatory osteoarthritis.

In one embodiment of the invention, the agent is an oligopeptide or a polypeptide. In a further embodiment, the agent is an antibody or a portion of an antibody such as a FAB fragment. In this embodiment the antibody is preferably human, partially human, chimeric, or a humanized antibody.

In another embodiment, the agent is a nonpeptidyl agent. For example, the nonpeptidyl agent AMD3100 (Donzella, G.A., et al (1998), AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor, Nature Medicine, 4:72-77).

AMD3100 is a bicyclam derivative and is representative of this class of chemicals. See DeVreese, K. et al., Antiviral Research 29, 209-219 (1996).

-8-

This invention provides a composition for treating rheumatoid arthritis comprising effective amounts of an agent capable of blocking the activation of the CXCR4 by SDF-1 and a pharmaceutically acceptable carrier. In an embodiment, the agent is oligopeptide. In another embodiment, the agent is a polypeptide. In a further embodiment, the agent is an antibody or a portion of an antibody, such as a FAB receptor. Preferably, the antibody is a human, humanized or chimeric antibody.

Pharmaceutically acceptable carriers are well-known to those skilled in the art and include, but are not limited to, 0.01-0.1M and preferably 0.05M phosphate buffer or 0.8% saline. Additionally, such pharmaceutically acceptable carriers may be aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers such as those based on Ringer's dextrose, and the like. Preservatives and other additives may also be present, such as, for example, antimicrobials, antioxidants, chelating agents, inert gases and the like.

The agent may be administered orally, parenterally or intra-articularly.

In another embodiment of the invention, the agent is a nonpeptidyl agent, such as the nonpeptidyl agent AMD3100.

5 This invention also provides a method for determining whether an agent is capable of inhibiting the activation of a CXCR4 receptor by SDF-1 comprising: (a) contacting cells expressing the CXCR4 receptor in the presence of SDF-1 with the agent under conditions permitting activation of the CXCR4 receptor by SDF-1 if the agent is absent; and (b) determining whether the amount of activation of the CXCR4 receptor by SDF-1 is decreased in the presence of the agent relative to the amount of activation in its absence, such  
10 a decrease in the amount of activation indicating that the agent is capable of inhibiting the activation of the CXCR4 receptor by SDF-1. In one embodiment, the CXCR4 receptor is a human CXCR4 receptor. In a further embodiment the cells are lymphocytes or monocytes. In yet another  
15 embodiment the CXCR4 receptor is expressed in prokaryotic or eukaryotic cells, including but not limited to bacterial, fungal, plant or animal cells using methods well known in the art.

20 Finally, this invention provides an agent identified by the above-described method and a composition comprising an amount of an agent identified by the above-described method effective to inhibit the activation of the CXCR4 receptor by SDF-1 and a suitable carrier.

25 This invention will be better understood from the Experimental Details which follow. However, one skilled in the art will readily appreciate that the specific methods and results discussed are merely illustrative of the  
30 invention as described more fully in the claims which follow thereafter.

**EXPERIMENTAL DETAILS****First Series of Experiments**

5      **Synoviocyte culture.** Synovial tissue was obtained at the  
time of joint replacement from a classic rheumatoid  
arthritis with 10-12 layers of hyperplastic lining cells  
which intensively expressed HLA-DR and HLA-DQ molecules,  
and showed replacement of the superficial lining layer with  
10      monocytoïd cells and an extensive subintimal infiltration  
of lymphocyte aggregates and monocytes. The osteoarthritis  
sample was taken from a synovium that had no lining cell  
hyperplasia and no subintimal cellular infiltration. The  
tissue was minced, enzymatically dissociated and cultured  
15      through five passages in Isocove's Modified Dulbecco's  
Media (Gibco, Grand Island, NY) supplemented with selected  
lots of 10% fetal calf serum (Gibco, Grand Island, NY) and  
1% penicillin-streptomycin (Sigma, St. Louis, MO) as  
described(5). The resulting cells which presumably  
20      included intimal and subintimal synoviocytes in varying  
proportions according to their proportion in the starting  
material were grown to confluence and passaged by brief  
exposure to dilutions of 1% trypsin-EDTA (Sigma, St. Louis,  
MO).

25

**Construction of the subtraction library and preliminary  
sequencing.** PolyA+ RNA was isolated from the fifth passage  
synoviocytes using a mRNA Isolation Kit (Stratagene). 2ug  
30      of twice purified polyA+ RNA was used as a template for  
cDNA synthesis in the RiboClone cDNA Synthesis System  
(Promega). The synthesized cDNA was ligated with the  
oligonucleotides GATCCGCGGCCGC and GCGGCCGCGT as  
described(26). After selection of fragments larger than  
35      250 nucleotides by fractionation through a Sephacryl S-400  
column (Pharmacia) and phosphorylation with T4  
polynucleotide kinase, the cDNA was digested with the

restriction enzyme MboI. The fragments were then ligated with oligonucleotides J-Bam-24 ACCGACGTCGACTATCCATGAACG and J-Bam-12 GATCCGTTCATG, and amplified as described(26). The PCR products, after fractionation through Sephacryl S-400 column, were digested with MboI and they comprised the primary amplicon. DNA from rheumatoid arthritis synoviocytes was further ligated with oligonucleotides N-Bam-24 AGGCAACTGTGCTATCCGAGGGAG and N-Bam-12 GATCCTCCCTCG. The hybridization was performed as described(26) except that the ratio of tester and driver was kept 1:100 throughout. 10ug of the osteoarthritis primary amplicon were hybridized with 0.1ug of the rheumatoid arthritis primary amplicon in 5ul of 24mM EPPS, pH8.0, 1mM EDTA, 1M NaCl for 20hr at 67C. The hybridized DNA was subjected to 10 cycles of PCR with N-Bam-24 as a primer, followed by digestion with mung bean nuclease. One four hundredth of the digests was further amplified for 20 cycles. After digestion with MboI, the DNA product was ligated with oligonucleotides R-Bam-24 AGCACTCTCCAGCCTCTCACCGAG and R-Bam-12 GATCCTCGGTGA. Hybridization and amplification steps were repeated. After redigestion with MboI, the resulting differentially subtracted cDNA fragments were cloned into a BamHI site of the plasmid pUC18. The recombinants were inoculated in an ordered grid pattern on nitrocellulose filters, which were then probed with the osteoarthritis cDNA amplicon <sup>32</sup>P-labeled with the Megaprime DNA labeling System (Amersham). The DNA sequence of the non-hybridized recombinants was determined in an Applied Biosystems DNA Sequencer Model 373A or 377 using standard dye terminator chemistry. The segman module of the Lasergene program (DNASTar) was used for identification of homologous recombinants and grouping them into groups. The Genman module of the Lasergene program was used to search the GenBank databases including the expressed sequence tag database on CDROM. BLAST was used to verify the identification of sequences that showed no homology with entries in the CDROM database.

**Northern blot analysis.** Probes were prepared from the clones by PCR amplification of the inserts, digestion with MboI and isolation by electrophoresis on a 1% agarose gel. 5  
1 µg of the once purified polyA+ RNA of the same preparation used for the construction of subtraction library was run on a 1% agarose gel, containing 1.9% formaldehyde and hybridized with the <sup>32</sup>P-labelled probes as described(28). 10  
The membranes were re-probed several times after stripping off the previous probe.

**Construction of a rheumatoid arthritis cDNA library.** The same preparation of the cDNA from the rheumatoid arthritis patient used for the construction of the subtraction 15  
library was ligated with EcoRI adapters. These constructs were cloned into λgt10 by standard procedures and the library was screened as described previously(29).

## **EXPERIMENTAL RESULTS**

20  
**Identification of genes differently represented in the cultured rheumatoid arthritis and osteoarthritis synoviocytes.** To identify genes that may be differently expressed in the cultured rheumatoid arthritis and 25  
osteoarthritis synoviocytes, cell lines originating from a carefully selected highly inflammatory rheumatoid arthritis synovium and an osteoarthritis synovium with no lining cell hyperplasia or inflammatory cell infiltration were chosen. Two subtraction cycles were performed between polyA+ RNA 30  
from fifth passage rheumatoid arthritis and osteoarthritis synoviocytes followed by negative screening of the resulting difference representation clones with a probe consisting of the <sup>32</sup>P-labelled osteoarthritis synovial fibroblastoid cDNA amplicons (Fig. 1). 319 recombinant 35  
clones were selected for further analysis by DNA sequencing.

Nucleotide sequencing revealed that many of those 319 recombinants had the same sequence, comprising of distinct 24 sequence groups. As would be expected, the number of recombinants representing each group varied considerably, ranging from just one to as many as 77 recombinants (Table 1). Comparison of the sequence with the GenBank database revealed that 16 sequence groups showed more than 97% homology with the previously identified human genes (Table 1). In the case of insulin-like growth factor binding protein 5 (IGFBP5) and interferon-inducible 56kd protein (II56kd protein) two cDNA fragments derived from the different portion of the same gene.

	<u>Name of gene</u>	<u>Number of Clones</u>
15	<b>Group 1 *</b>	
	Manganese superoxide dismutase	8
	Collagenase type IV	4
	Complement factor B	4
	$\alpha$ -B crystallin	1
20	Interferon-gamma IEF SSP 5111	1
	B94 protein	1
	HLA-E heavy chain	1
	NMB protein	9
	Muscle fatty-acid-binding protein	1
25	<b>Group 2 *</b>	
	VCAM-1	2
	II56kdprotein	42
	71kd 2'-5'-oligoadenylate synthetase	1
30	Mac2 binding protein	21
	Biglycan	16
	Lumican	3
	IGFBP5	107
	SDF-1- $\alpha$	69
35	Semaphorin VI	1

Table 1. List of the identified genes and number of obtained clones.

-14-

On Northern blot analysis, Group 1 genes showed little difference in the intensity of hybridization between cultured rheumatoid and osteoarthritis synoviocyte RNA. Group 2 genes exhibited overexpression in rheumatoid arthritis synoviocytes compared with osteoarthritis synoviocyte. In the case of the genes that were represented in two different sequence groups, a total number of clones are shown in the table. Those genes are II56kd protein, 8 + 34, IGFBP5, 30 + 77, and SDF-1 $\alpha$  28 + 41.

10

**Characterization of novel genes.** Of the remaining 8 sequence groups, two highly represented clones with copy numbers of 28 and 41 in the library had 32% and 25% similarity, respectively, to the 3'-untranslated region of the mouse SDF-1 $\alpha$ . These fragments hybridized with the same clones from the  $\lambda$ gt10 rheumatoid arthritis synoviocyte library, indicating that they derived from the same transcript.

20

The nucleotide sequence of the clones showed high homology with mouse SDF-1 $\alpha$  in the coding region (data not shown), and was almost identical with the subsequently published sequence of the human SDF-1 $\alpha$  gene(30).

25

Another clone was found to have 90% homology with mouse semaphorin E at the nucleotide level and 94% at the putative amino acid level. This suggested that the isolated clone was a human homologue of the mouse semaphorin E, and it was tentatively named human "semaphorin VI". A comparison of the amino acid sequences with the previously described human semaphorins III, IV, V and mouse semaphorin E is shown in Fig. 2.

30

Analysis of another clone showed some homology at the nucleotide level and more significantly at the putative amino acid sequence level with a variety of sulfatases.

35



-15-

Among human genes the greatest similarity was with the human N-acetyl-glycosamine sulfatase. However the sequence of this clone was most homologous with the putative amino acid sequence derived from the *C. elegans* genomic cosmid KO9C (Fig. 3).

A portion of the sequence of clone ML2115 was 99% identical with the EST sequence AA447232. The remaining clones did not show significant homology to any known genes in either nucleotide level nor in translated amino acid level, and their identification is continuing.

**Northern analysis.** To determine the actual difference in level of expression of the genes characterized by the 24 different recombinant clones, Northern analysis of polyA+ RNA from the two cell lines used to make the difference library was performed. The level of GAPDH expression was not detectably different between both synoviocytes (data not shown). Fig. 4 illustrates a representative gel using inserts of clones as probes from, lumican, IGFBP5, SDF-1 $\alpha$ , semaphorin VI, collagenase type IV and the two clones, ML2122 and ML2115 which did not show appreciative homology to the known genes. As shown, the expression of collagenase type IV did not differ significantly between the two RNA preparation. Similarly, the expression of genes depicted in Group 1, Table 1, such as HLA-E,  $\alpha$ -B-crystallin and manganese superoxide dismutase had minimally increased or essentially equivalent levels of expression in the osteoarthritis and rheumatoid arthritis synoviocyte cell lines.

However, of the genes identified in this study, 11 had moderate to marked differentially elevated expression in the rheumatoid arthritis synoviocyte line used for the subtraction (Table 1. Group 2), suggesting that these genes were constitutively overexpressed in cultured rheumatoid arthritis synoviocytes. These 11 genes included: VCAM-1,

-16-

Mac-2 binding protein (Mac-2BP), IGFBP5, biglycan, lumican, SDF-1 $\alpha$ , 115kd protein, 71kd 2'-5' oligoadenylate synthetase, semaphorin VI, and two clones ML2115 and ML2122. The clone ML2115 hybridized with a 6 kb mRNA. The clone ML2122 hybridized with three species of mRNA of which 4.7 kb was the major one (Fig. 4). The characterization of these clones is being continued.

Since SDF-1 $\alpha$  has an alternatively spliced form SDF-1- $\beta$  with which it shares the most of coding region but a different 3'-untranslated region(30), the expression of SDF-1 $\beta$  was investigated. Its expression was also found to be increased in parallel with that of SDF-1 $\alpha$  in the rheumatoid arthritis synoviocytes compared to the osteoarthritis cells (data not shown).

#### EXPERIMENTAL DISCUSSION

The objective of the present study was to develop a method to identify additional genes that comprise the distinctive biochemical and cell physiologic phenotype of cultured rheumatoid arthritis fibroblastoid synoviocytes. Of 24 genes characterized by this procedure, 11 were found to be constitutively overexpressed by Northern analysis in the rheumatoid arthritis synoviocyte culture used for subtraction and three were novel genes. The relatively unbiased gene discovery approach used to subtract differential representations of the expressed genes in the two prototype cell lines is a general method useful for the identification of differentially expressed genes. The characteristics of the genes identified in the present study direct increased attention to the possibilities that synoviocytes from synovia with marked lining cell hyperplasia are characterized both by different matrix and cell-cell interactions and by the fact that they likely provide guidance clues and sites for receptor interaction to infiltrating monocytes and lymphocytes during normal

-17-

histogenesis of the synovial lining, providing a mechanism for the location of monocyte lineage cells in the intimal layer. Moreover, in an exaggerated mode of leukocyte ingress that could occur during synovial hyperplasia, these gene products might foster the localization of an immune or autoimmune response to the joint. Taken together the results direct further attention to the role of mesenchymal cells in immune-mediated diseases.

10 In the present experiments special attention was directed to the selection of the tissue source of the two cell lines used in the subtraction. Prior studies showed that cell lines obtained from patients clinically characterized as osteoarthritis with various degrees of inflammatory synovitis elaborated proinflammatory cytokines in patterns often similar to those found in rheumatoid arthritis samples(16,25). In this study the reference synovial sample was from a patient with osteoarthritis who had no evidence of synovitis with only a single cell layer of intimal synoviocytes. In contrast the rheumatoid arthritis synovium used for gene isolation had 10-12 layers of hyperplastic lining cells. It should be stressed that a limitation of this study is that it is not possible to identify the site of origin in the synovial lining of the cultured synoviocytes, although application of reagents directed to identification of these products of these genes *in situ* should facilitate resolving the question of their origin.

30 The gene discovery approach used in this work was initially developed to detect the absolute difference between two genomes where each gene is present in the same ratio(26). Because of the differences in the number of each mRNA species and the likelihood that the frequencies of certain mRNA species relatively differed between cultured rheumatoid arthritis and osteoarthritis synoviocytes, the subtraction steps were modified by reducing the ratio of

-18-

the tester and driver DNA. This had the effect of decreasing the completeness of the subtraction step, but increasing the possibility of discovering genes expressed at a variety of different levels in the two cell lines. To  
5 compensate for any potential inefficiency of subtraction, a negative selection screening step was added using the driver osteoarthritis synoviocyte cDNA amplicon as a probe, and the constitutive increase in expression of the identified genes was confirmed in Northern analysis.

10 Several technical points require comment. The cDNA synthesis was primed with oligo (dT) to bias the ultimate library, towards one rich in 3'-untranslated regions, because the nucleotide sequence of this region is more  
15 divergent than that of the coding regions. The restriction enzyme MboI was chosen to create DNA fragments of relatively small size to facilitate efficient and even amplification by PCR, and to increase the chance of isolating genes which are differentially spliced and/or  
20 members of a supergene family. The DNA fragments were fractionated through a Sephacryl S-400 column to avoid biased amplification of numerous fragments smaller than 250 nucleotides.

25 The subtractive method is less influenced by differences in a low copy number mRNA species than the related differential display method, however the number of recombinants analyzed places a sampling error limit on the identification of a rare species. In the present study,  
30 some differentially expressed genes were identified only by the presence of a single recombinant. There are additional technical reasons, such as the absence of appropriate Mbo I sites why some genes previously expressed in cultured inflammatory synoviocytes might not be  
35 identified(16,25,31).

Of the 11 genes constitutively increased in expression in

the rheumatoid synoviocytes, VCAM-1, a 110kd member of the immunoglobulin gene superfamily, and Mac-2BP, also termed '90k tumor associated protein', both exhibit properties that suggest they could mediate heterotypic binding of monocyte-lineage intimal synoviocytes to fibroblastoid lineage synoviocytes. VCAM-1 has been previously described as markedly increased on rheumatoid arthritis synoviocytes(1,23) and the identification of VCAM-1 by this difference method supports the validity of this gene discovery approach for intimal synoviocytes. VCAM-1 binds circulating monocytes and lymphocytes expressing the  $\alpha_4\beta_1$  (VLA4) integrin. Mac-2BP, a heavily N-glycosylated secreted protein which binds stoichiometrically to the macrophage-associated lectin Mac-2 (galectin-3)(32,33), also binds to the monocyte CD14 structure in the presence of LPS and LBP(34). Binding of Mac-2BP to these receptors initiates monocyte-lineage cells to secrete IL-1 and IL-6 and increases their expression of ICAM-1(35,36). This alteration in monocyte state could be one of the factors modulating the cell into a synovial lining macrophage.

The overexpression of the semaphorin VI by synoviocytes is intriguing because the semaphorins are a family of transmembrane signalling and secreted guidance glycoprotein molecules that are implicated in directing axonal extension(37). However, in view of the relatively small number of axons in the synovium, it seems unlikely that the physiologic role of the semaphorin VI molecule is to signal through an axonal receptor. Rather, one might conjecture semaphorin VI plays some role in chemotaxis of monocytes and their differentiation. Suggesting a broader role of semaphorin molecules in cellular interaction, CD100 which plays a role in B-cell activation parallel to that of CD40 ligand has recently been identified as a member of this family(38). A report of the overexpression of semaphorin VI gene in rheumatoid arthritis synovial fibroblastoid cells by the differential display method appeared while

this manuscript was in preparation(39).

Another molecule constitutively expressed by the rheumatoid synoviocyte was the chemokine SDF-1 $\alpha$ . It was first identified as a pre-B cell growth stimulating factor produced by marrow stromal cells(40,41). SDF-1- $\alpha$  attracts pro- and pre-B cells(42) as well as CD34+ hematopoietic progenitor cells(43). Mice genetically deficient for SDF-1 $\alpha$  lack B-cells and have hematopoiesis only in their liver(44). SDF-1 $\alpha$  is the ligand for the CXCR-4 chemokine receptor that serves as a co receptor for entry of T-tropic syncytial inducing forms of HIV into T-cells(45). SDF-1 $\alpha$  has recently been the subject of an interesting series of studies that demonstrated this chemokine to be a highly efficacious transendothelial chemoattractant for both monocytes and T-lymphocytes(46). It is not clear that SDF-1 $\beta$  has a biologic activity different from that of SDF-1 $\alpha$  at the moment. We speculate that the production of SDF-1 by intimal synoviocytes in the normal joint could act as a guidance cue for the continual entrance into the intimal synovial membrane of monocyte lineage precursors committed to differentiation into phagocytic lining cells. Similarly SDF-1 and other chemokines elaborated by the normal synoviocytes may act to enhance the ingress of lymphocytes into the joint tissues to facilitate physiologic surveillance functions.

Several genes were identified as constitutively expressed, indicating the possibility of altered cell-matrix interactions as part of the distinctive rheumatoid arthritis synoviocyte phenotype. Lumican is a keratan sulfate proteoglycan that plays a critical role in the basis of corneal transparency(47). In adult cartilage lumican exists predominantly in a glycoprotein form lacking keratan sulfate(48). Macrophages do not adhere to intact corneal keratan sulfate proteoglycans but attach and spread rapidly on the lumican core protein after the removal of

-21-

keratan sulfate chains(49). This observation suggests some species of lumican could also act to localize macrophages to sites of the synovium. Biglycan, a dermatan sulfate-proteoglycan, is both induced by TGF- $\beta$ , and binds TGF- $\beta$ (50), suggesting that biglycan may down regulate TGF- $\beta$  activity by sequestering this growth factor in the extracellular matrix. IL-6 stimulates the expression of biglycan, while TNF- $\alpha$  depresses its expression(51). IGFBP5, was the most highly represented species in the difference library. This molecule increases IGF-1 binding to the fibroblast membrane by attaching to the extracellular-matrix proteins, types III and IV collagen, laminin and fibronectin(52). IGFBP5 may have an antiinflammatory role that opposes the effect exhibited by IL-1 and TNF- $\alpha$  of stimulating proteoglycan degradation and decreasing proteoglycan synthesis(53). The observation that IGFBP5 is further induced by exposure of cells to prostaglandin E2(54) is of interest with respect to the pattern of morphologic change and gene activation observed in synoviocyte cultures upon addition of this agent(55).

The 71kd 2'-5' oligoadenylate synthetase is a subunit of one of several interferon-induced enzymes that, when activated by double-stranded RNA, convert ATP into 2'-5' linked oligomers of adenosine(56). The interferon-inducible 56kd protein is of unknown function, but is common with 2'-5' oligoadenylate synthetase is strongly induced by interferons(57). The expression of these two genes directs attention to the presence of activation-like features in the phenotype of the rheumatoid arthritis synoviocytes.

In prior studies it was found that the relative overexpression of known genes comprising the distinctive phenotype of cultured inflammatory synoviocytes varied somewhat from cell line to cell line (16,25). Preliminary evidence using these newly isolated genes indicates similar

-22-

sample to sample variation in the relative degree of expression of one overexpressed gene relative to another by Northern analysis. Similarly, additional studies will be required to determine whether the levels of expression of the remaining genes that were not preferentially overexpressed in rheumatoid synoviocytes distinguish synoviocytes in general from fibroblastoid cells in other anatomic sites.

The identification of a group of constitutively overexpressed genes in this study is relevant to the three principal cell biologic possibilities explaining the origin of the distinctive phenotype of these cultured rheumatoid synoviocytes. We and others have postulated that the phenotype could result from sustained modulation of gene expression in several fibroblast lineage cells of the joint that developed as a response to prolonged paracrine signalling through products of a local immune response, analogous to a phenotypic imprinting process(2). A second possibility is that the cells are primarily 'transformed' as suggested by Gay and colleagues(9). However, perhaps most likely in view of the features of the genes isolated in this study, is a third possibility that the phenotype exhibited by these cells is similar to that of the normal intimal synoviocyte. Thus at the start of an experiment, a culture derived from rheumatoid arthritis synovia characterized by marked intimal synoviocyte hyperplasia would contain an increased proportion of intimal lining synoviocytes that are responsible for the resulting phenotype of the cultured cells because of their lineage difference in patterns of gene expression.

Each of these three potential origins shares in common the possibility that the presence of increased quantities of these guidance and cell interaction molecules may itself create a novel synovial microenvironment that could facilitate interactions with monocyte lineage cells and



5 foster the entry of large numbers of inflammatory and  
immune leukocytes. The first two mechanisms imply that the  
contribution of synoviocytes to the cell biologic basis of  
synovitis is qualitatively based due to the presence of  
10 abnormally activated or modulated cells while the third  
mechanism implies a quantitative over representation of  
members of a normal cell lineage that physiologically  
exhibits distinctive properties. In each case, the  
resulting environment may modulate or deviate an ongoing  
10 immune response and reenforce its subsequent evolution into  
an autoimmune process.

15 Since inflammatory imprinting or hyperplasia could be  
initiated by a non specific minor traumatic event or even  
driven by a local immune response to a common pathogen,  
this might provide a non antigen-specific mechanism for  
localizing potential pathogenic immune responses to the  
joint. For example, an additional action of SDF-1 at  
20 higher concentrations could be the facilitation of earlier  
stages of peripheral B-cell development in the synovial  
milieu that are relevant to the presence and maturation of  
abundant B-cells in the rheumatoid synovium and to their  
production of rheumatoid factors(58). Furthermore, several  
25 additional molecules produced by the synoviocyte can  
interact to facilitate other aspects of B-cell development.  
IL-6, a cytokine with effects on B-cell differentiation, is  
constitutively increased in synoviocytes obtained from  
rheumatoid arthritis patients(16) and its synthesis by  
monocytes is induced by Mac-2BP, as described above.  
30 Interleukin 7-dependent proliferation of pre-B cells is  
also enhanced upon exposure to biglycan(59). Similarly  
these molecules could attract and facilitate interaction  
with and activation of monocytes. For example, Mac-2BP  
which induces homotypic monocyte aggregation and  
35 activation(33) could be a factor present in supernatants  
from cultured rheumatoid arthritis synoviocytes that  
induces blood monocytes to form giant cells(60). Thus,

-24-

5 along with the variety of genes that mediate the well  
recognized effector functions of matrix remodelling and  
tissue destruction(55), the genes expressed by the  
mesenchymal cells of the joint may affect antigen non  
specific immune localization or amplification mechanisms  
that could play a role in the puzzling phenomenon of why  
localized joint inflammation develops in many disparate  
diseases in the setting of immune responses that apparently  
have little to do with the joint.

10

## REFERENECEES

2. Winchester R Rheumatoid Arthritis. Edited by MM Frank,  
KF Austen, HN Claman, ER Unanue. Sampter's  
5 Immunological Diseases: Boston, MA: Little, Brown  
and Company; 1995.
3. Barland P, Novikoff AB, Hamerman D Electron  
10 microscopy of the human synovial membrane. J Cell Biol  
1962;14:207-220.
4. Norton WL, Ziff M Electron microscopic observations  
in the rheumatoid synovial membrane. Arthritis Rheum  
15 1966;9:589-610.
5. Burmester GR, Dimitriu-Bona A, Waters SJ, Winchester  
RJ Identification of three major synovial lining cell  
populations by monoclonal antibodies directed to Ia  
antigens and antigens associated with  
20 monocytes/macrophages and fibroblasts. Scand J Immunol  
1983;17:69-82.
6. Edwards JC, Leigh RD, Cambridge G Expression of  
25 molecules involved in B lymphocyte survival and  
differentiation by synovial fibroblasts. Clin Exp  
Immunol 1997;108:407-414.
7. Morales-Ducret J, Wayner E, Elices MJ, Alvaro-Gracia  
30 JM, Zvaifler NJ, Firestein GS Alpha 4/beta 1 integrin  
(VLA4) ligands in arthritis. Vascular cell adhesion  
molecule-1 expression in synovium and on  
fibroblast-like synoviocytes. J Immunol  
1992;149:1424-1431.
8. Klareskog L, Forsum U, Scheynius A, Kabelitz D,  
35 Wigzell H Evidence in support of a self-perpetuating  
HLA-DR-dependent delayed-type cell reaction in

-26-

rheumatoid arthritis. Proc Natl Acad Sci USA  
1982;79:3632-3636.

- 5 9. Trabandt A, Aicher WK, Gay RE, Sukhatme VP, Nilson  
Hamilton M, Hamilton RT, et al Expression of the  
collagenolytic and Ras-induced cysteine proteinase  
cathepsin L and proliferation-associated oncogenes in  
synovial cells of MRL/I mice and patients with  
rheumatoid arthritis. Matrix 1990;10:349-361.
- 10 10. Firestein GS, Zvaifler NJ How important are T cells  
in chronic rheumatoid synovitis? Arthritis Rheum  
1990;33:768-73.
- 15 11. Arend WP, Dayer JM Cytokines and cytokine inhibitors  
or antagonists in rheumatoid arthritis. Arthritis  
Rheum 1990;33:305-15.
- 20 12. Koch AE, Kunkel SL, Burrows JC, Evanoff HL, Haines GK,  
Pope RM, et al Synovial tissue macrophage as a source  
of the chemotactic cytokine IL-8. J Immunol  
1991;147:2187-2195.
- 25 13. Winchester RJ, Burmester GR Demonstration of Ia  
antigens on certain dendritic cells and on a novel  
elongate cell found in human synovial tissue. Scand J  
Immunol 1981;14:439-444.
- 30 14. Werb Z, Mainardi CL, Vater CA, Harris ED, Jr.  
Endogenous activation of latent collagenase by  
rheumatoid synovial cells. N Engl J Med 1977;296:1017.
- 35 15. Castor CW, Ritchie JC, Scott ME, Whitney SL  
Connective tissue activation XI: stimulation of  
glycosaminoglycan and DNA formation by a platelet  
factor. Arthritis Rheum 1977;20:859-868.

16. Bucala R, Ritchlin C, Winchester R, Cerami A  
Constitutive production of inflammatory and mitogenic  
cytokines by rheumatoid synovial fibroblasts. J Exp  
Med 1991;173(3):569-574.
17. Smith CA Properties of synovial cells In culture. J  
Exp Med 1971;134:306S.
18. Wynne-Roberts CR, Castor CW Ultrastructural  
comparison of rheumatoid and nonrheumatoid synovial  
fibroblasts grown in tissue culture. Arthritis Rheum  
1972;15:65-83.
19. Anastassiades TP, Len J, Wood A, Irwin D The growth  
kinetics of synovial fibroblastic cells from  
inflammatory and noninflammatory arthropathies.  
Arthritis Rheum 1978;21:461-466.
20. Ponteziere C, Desmoulins D, Agneray J, Ekindjian OG,  
Cals MJ Comparative proliferation of non-rheumatoid  
and rheumatoid human synovial cells. Int J Tissue  
React 1990;12:229-236.
21. Goddard DH, Grossman SL, Moore ME Autocrine  
regulation of rheumatoid arthritis synovial cell  
growth in vitro. Cytokine 1990;2:149-155.
22. Winchester R, Su F, Ritchlin C Modulation of  
synoviocytes by inflammation - source of a persistent  
non-immunologic drive in synovitis: analysis of levels  
of mRNA expression by a simple multi-gene assay. Clin  
Exp Rheumatol 1993;11(S8):87-90.
23. Kriegsmann J, Keyszer GM, Geiler T, Brauer R, Gay RE,  
Gay S Expression of vascular cell adhesion molecule-1  
mRNA and protein in rheumatoid synovium demonstrated  
by in situ hybridization and immunohistochemistry. Lab

Invest 1995;72:209-214.

24. Ritchlin CT, Winchester RJ Potential mechanisms for coordinate gene activation in the rheumatoid synoviocyte: implications and hypotheses. Springer Semin Immunopathol 1989;11:219-234.
25. Ritchlin C, Dwyer E, Bucala R, Winchester R Sustained and distinctive patterns of gene activation in synovial fibroblasts and whole synovial tissue obtained from inflammatory synovitis. Scand J Immunol 1994;40:292-8.
26. Lisitsyn N, Wigler M Cloning the differences between two complex genomes. Science 1993;259:946-951.
27. Hubank M, Schatz DG Identifying differences in mRNA expression by representational difference analysis of cDNA. Nucleic Acids Res 1994;22:5640-5648.
28. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning: A laboratory Manual. 2nd edition. Cold Spring Harbor, N.Y., Cold Spring Harbor Laboratory, 1989
29. Seki T Identification of multiple isoforms of the low-affinity human IgG Fc receptor. Immunogenetics 1989;30:5-12.
30. Shirozu M, Nakano T, Inazawa J, Tashiro K, Tada H, Shinohara T, et al Structure and chromosomal localization of the human stromal cell- derived factor 1 (SDF1) gene. Genomics 1995;28:495-500.
31. Tan PL, Farmiloe S, Yeoman S, Watson JD Expression of the interleukin 6 gene in rheumatoid synovial fibroblasts. J Rheumatol 1990;17:1608-1612.

- 5 32. Koths K, Taylor E, Halenbeck R, Casipit C, Wang A  
Cloning and characterization of a human Mac-2-binding  
protein, a new member of the superfamily defined by  
the macrophage scavenger receptor cysteine-rich  
domain. J Biol Chem 1993;268:14245-14249.
- 10 33. Inohara H, Akahani S, Koths K, Raz A Interaction  
between galectin-3 and Mac-2-binding protein mediate  
cell-cell adhesion. Cancer Res 1996;56:4530-4534.
34. Yu B, Wright SD LPS-dependent interaction of  
Mac-2-binding protein with immobilized CD14. J Inflamm  
1995;45:115-125.
- 15 35. Iacobelli S, Arno E, D'Orazio A, Coletti G Detection  
of antigen recognized by a novel monoclonal antibody  
in tissue and serum from patients with breast cancer.  
Cancer Res 1986;46:3005-3010.
- 20 36. Ullrich A, Sures I, D'Egidio M, Jallal B, Powell TJ,  
Herbst R, et al The secreted tumor-associated antigen  
90K is a potent immune stimulator. J Biol Chem  
1994;269:18401-18407.
- 25 37. Luo Y, Shepherd I, Li J, Renzi MJ, Chang S, Raper JA  
A family of molecules related to collapsin in the  
embryonic chick nervous system. Neuron  
1995;14:1131-1140.
- 30 38. Hall KT, Boumsell L, Schultze JL, Boussiotis VA,  
Dorfman DM, Cardoso AA, et al Human CD100, a novel  
leukocyte semaphorin that promotes B-cell aggregation  
and differentiation. Proc Natl Acad Sci USA  
1996;93:11780-5.
- 35 39. Mangasser-Stephan K, Dooley S, Welter C, Mutschler W,  
Hanselmann RG Identification of human semaphorin E

gene expression on rheumatoid synovial cells by mRNA differential display. *Biochem Biophys Res Commun* 1997;234:153-156.

- 5 40. Nagasawa T, Kikutani H, Kishimoto T Molecular cloning and structure of a pre-B-cell growth- stimulating factor. *Proc Natl Acad Sci USA* 1994;91:2305-2309.
- 10 41. Tashiro K, Tada H, Heilker R, Shirozu M, Nakano T, Honjo T Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. *Science* 1993;261:600-603.
- 15 42. D'Apuzzo M, Rolink A, Loetscher M, Hoxie JA, Clark-Lewis I, Melchers F, et al The chemokine SDF-1, stromal cell-derived factor 1, attracts early stage B cell precursors via the chemokine receptor CXCR4. *Eur J Immunol* 1997;27:1788-1793.
- 20 43. Ajuti A, Webb IJ, Bleul C, Springer T, Gutierrez-Ramos JC The chemokine SDF-1 is a chemoattractant for human CD34+ hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. *J Exp Med* 1997;185:111-120.
- 25 44. Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, et al Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. *Nature* 1996;382:635-8.
- 30 45. Bleul CC, Farzan M, Choe H, Parolin C, Clark-Lewis I, Sodroski J, et al The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry. *Nature* 1996;382:829-32.
- 35



-31-

46. Bleul CC, Fuhlbrigge RC, Casasnovas JM, Aiuti A, Springer TA A highly efficacious lymphocyte chemoattractant, stromal cell-derived factor 1 (SDF-1). J Exp Med 1996;184:1101-9.
- 5 47. Rada JA, Cornuet PK, Hassell JR Regulation of corneal collagen fibrillogenesis in vitro by corneal keratan sulfate proteoglycan (lumican) and decorin core proteins. Exp Eye Res 1993;56:635-48.
- 10 48. Grover J, Chen ZN, Korenberg JR, Roughley PJ The human lumican gene. Organization, chromosomal location, and expression in articular cartilage. J Biol Chem 1995;270:21942-21949.
- 15 49. Funderburgh JL, Mitchler RR, Funderburgh ML, Roth MR, Chapes SK, Conrad GW Macrophage receptors for lumican. Invest Ophthalmol Vis Sci 1997;38:1159-1167.
- 20 50. Hildebrand A, Romaris M, Rasmussen LM, Heinegard D, Twardzik DR, Border WA, et al Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. Biochem J 1994;302:527-534.
- 25 51. Ungefroren H, Krull NB Transcriptional regulation of the human biglycan gene. J Biol Chem 1996;271:15787-15795.
- 30 52. Jones JI, Gockerman A, Busby WH, Jr, Camacho-Hubner C, Clemmons DR Extracellular matrix contains insulin-like growth factor binding protein-5: potentiation of the effects of IGF-I. J Cell Biol 1993;121:679-687.
- 35 53. Tyler JA Insulin-like growth factor 1 can decrease degradation and promote synthesis of proteoglycan in

-32-

cartilage exposed to cytokines. Biochem J  
1989;260:543-548.

- 5 54. Pash JM, Canalis E Transcriptional regulation of  
insulin-like growth factor-binding protein-5 by  
prostaglandin E2 in osteoblast cells. Endocrinology  
1996;137:2375-2382.
- 10 55. Krane SM, Dayer JM, Simon LS, Byrne MS Mononuclear  
cell-conditioned medium containing mononuclear cell  
factor (MCF), homologous with interleukin 1,  
stimulates collagen and fibronectin synthesis by  
adherent rheumatoid synovial cells: effects of  
15 prostaglandin E2 and indomethacin. Coll-Relat-Res  
1985;5:99-117.
- 20 56. Marie I, Hovanessian AG The 69-kDa 2-5A synthetase is  
composed of two homologous and adjacent functional  
domains. J Biol Chem 1992;267:9933-9939.
- 25 57. Wathelet M, Moutschen S, Defilippi P, Cravador A,  
Collet M, Huez G, et al Molecular cloning,  
full-length sequence and preliminary characterization  
of a 56-kDa protein induced by human interferons. Eur  
J Biochem 1986;155:11-17.
- 30 58. Mellors RC, et.al. Rheumatoid factor and the  
pathogenesis of rheumatoid arthritis. J Exp Med  
1961;113:475.
- 35 59. Oritani K, Kincade PW Identification of stromal cell  
products that interact with pre-B cells. J Cell Biol  
1996;134:771-782.
60. Grimley PM, Sokoloff L Synovial giant cells in  
rheumatoid arthritis. Am J Pathol 1966;49:931.

### Second Series of Experiments

5       **Immunolocalization of SDF-1 and CXCR-4 to different cells  
in the joints of patients with rheumatoid arthritis.**

10       **Objective:** In support of the prior observation of the  
synthesis of SDF-1 on Northern analysis by cultured  
synovial lining cells from rheumatoid arthritis and other  
forms of inflammatory arthritis, the synovial tissues of  
patients with rheumatoid arthritis were studied using a  
polyclonal goat anti SDF-1 antibody. Similarly, the tissue  
was studied for the expression of CXCR4, the receptor for  
SDF-1

15       **Results:** The hyperplastic layer of fibroblastoid synovial  
lining cells showed intense staining for the presence of  
SDF-1. The lymphocytes and monocytes infiltrating in the  
sub lining cell region of the joint exhibited intense  
20       staining for the expression of CXCR4. Similarly, the  
monocyte-lineage cell in the synovial lining, but not the  
fibroblastoid synovial lining cells also expressed CXCR4.

25       **Interpretation:** The observations are consistent with the  
first series of experiments. That SDF-1 is made by  
fibroblastoid synovial lining cells and that this chemokine  
attracts lymphocytes and monocytes into the joint tissue to  
cause joint inflammation.

30       **Third Series of Experiments**

Expression of Chemokine SDF-1 by Intimal Synoviocytes

35       The chemokine stromal derived factor-1 (SDF-1) was first  
identified as a pre-B cell growth stimulating factor  
produced by marrow stromal cells necessary for its  
population by pro- and pre-B cells and CD34+ hematopoietic

-34-

progenitor cells. SDF-1 has known to be a highly efficacious transendothelial chemooattractant for monocytes and T-cells. The SDF-1 receptor, CxCR4, also serves as a co-receptor for HIV entry into T cells. We identified SDF-1 as a gene overexpressed by cultured synovial fibroblastoid cells from an individual with rheumatoid arthritis (RA) compared with those from osteoarthritis (OA) by differential subtraction. To investigate whether SDF-1 is generally overexpressed in RA synovial fibroblastoid cell lines, Northern analysis was performed with RNA from fibroblastoid cell lines of 11 RA and 2 OA samples. 8 of the RA lines were from synova with marked lining cell hyperplasia, massive inflammatory infiltration and neovascularization. All 8 exhibited moderate to marked overexpression of SDF-1. The remaining 3 RA individuals had only mild infiltration with little lining cell hyperplasia but considerable neovascularization. These 3 RA and 2 noninflammatory OA cell lines had much lower expression of SDF-1, suggesting a correlation between the level of SDF-1 expression in synoviocyte lines and features of the tissue from which they were derived. Staining of synovial tissues from 3 OA and 2 RA synovia with a polyclonal antibody to SDF-1 revealed 60-70% positivity of intimal synoviocytes in OA. In RA there was markedly stronger and more extensive SDF-1 staining in the hyperplastic lining with additional staining of some subintimal fibroblastoid cells. The results suggest that increased SDF-1 elaboration by intimal synoviocytes and possible other fibroblastoid cells may participate in the pathology of RA by enhancing recruitment of monocytes and T-lymphocytes into the synovium.

What is claimed is:

- 5 1. A method for treating rheumatoid arthritis or other forms of inflammatory arthritis which comprises administering to a subject an amount of an agent effective to inhibit the activation of the CXCR4 receptor by SDF-1.
- 10 2. The method of claim 1, wherein the agent is oligopeptide or a polypeptide.
3. The method of claim 1, wherein the agent is an antibody or a portion of an antibody.
- 15 4. The method of claim 3, wherein the antibody is a human, chimeric or humanized antibody or portion thereof.
- 20 5. The method of claim 1, wherein the agent is a nonpeptidyl agent.
6. The method of claim 6, wherein the nonpeptidyl agent is a bicyclam such as AMD3100.
- 25 7. A composition for treating rheumatoid arthritis comprising an effective amount of an agent capable of inhibiting the activation of the CXCR4 receptor by SDF-1 and a pharmaceutically acceptable carrier.
- 30 8. The composition of claim 7, wherein the agent is oligopeptide or a polypeptide.
9. The composition of claim 7, wherein the agent is an antibody or a portion of an antibody.
- 35 10. The composition of claim 9, wherein the antibody is a human chimeric, or humanized antibody.

11. The composition of claim 7, wherein the agent is a nonpeptidyl agent.
- 5 12. The composition of claim 11, wherein the nonpeptidyl agent is a bicyclam such as AMD3100.
13. A method for determining whether an agent is capable of inhibiting the activation of a CXCR4  
10 receptor by SDF-1 comprising:
- (a) contacting the cells expressing CXCR4 receptor in the presence of SDF-1 with the agent under condition permitting activation of the CXCR4  
15 by SDF-1 if the agent is absent; and
- (b) determining whether the amount of activation of the CXCR4 receptor by SDF-1 is decreased in the presence of the agent relative to the  
20 amount of activators in its absence, such a decrease in the amount of activation indicating that the agent is capable of inhibiting the activation of the CXCR4  
25 receptor by SDF-1.
14. The method of claim 13, wherein the cells are lymphocytes or monocytes.
15. The method of claim 13, wherein the cells are  
30 bacterial, fungal, plant, or animal cells.
16. An agent identified by the method of claim 13.
17. A composition comprising an amount of an agent  
35 identified by the method of claim 13 effective to inhibit the activation of the CXCR4 receptor by SDF-1 and a suitable carrier.

FIG. 1




FIG. 2


SAVCVYHLLSDIQ	TVFNGPFAHKEGPNHQ	LSYQGR	IPYPR	m	semaphorin E
SAVCVYHLLSDIQ	TVFNGPFAHKEGPNHQ	LSYQGR	IPYPR	h	semaphorin VI
SAVCVYHLLSDIQ	TVFNGPFAHKEGPNHQ	LSYQGR	IPYPR	h	semaphorin IV
SAVCVYHLLSDIQ	TVFNGPFAHKEGPNHQ	LSYQGR	IPYPR	h	semaphorin V
SAVCVYHLLSDIQ	TVFNGPFAHKEGPNHQ	LSYQGR	IPYPR	h	semaphorin II
PGTCPGGALTPNM	TKDFFPDDVV	IRNHPLMYNS	ISPI	m	semaphorin E
PGTCPGGALTPNM	TKDFFPDDVV	IRNHPLMYNS	ISPI	h	semaphorin VI
PGTCPGGALTPNM	TKDFFPDDVV	IRNHPLMYNS	ISPI	h	semaphorin IV
PGTCPGGALTPNM	TKDFFPDDVV	IRNHPLMYNS	ISPI	h	semaphorin V
PGTCPGGALTPNM	TKDFFPDDVV	IRNHPLMYNS	ISPI	h	semaphorin II
HRRLIIRIGTDYK	YTKIAVD			m	semaphorin E
HRRLIIRIGTDYK	YTKIAVD			h	semaphorin VI
HRRLIIRIGTDYK	YTKIAVD			h	semaphorin IV
HRRLIIRIGTDYK	YTKIAVD			h	semaphorin V
HRRLIIRIGTDYK	YTKIAVD			h	semaphorin II



FIG. 3

S	Y	P	A	P	H	G	P	E	D	P	A	P	Q	F	A	H	M	E	E	I	S	H	R	T	G	S	W	N	F	A	P	N	P	D	K	Q	W	L	L	Q	R	T	CELK09C4		
S	H	A	A	P	H	G	P	E	D	S	A	P	Q	F	S	E	L	Y	P	N	A	S	Q	H	I	T	P	S	Y	N	F	A	P	N	M	D	K	H	W	I	M	Q	Y	T	ts99
A	T	P	A	P	H	S	P	W	T	A	A	P	Q	Y	Q	K	A	E	Q	N	V	F	A	P	R	N	K	N	F	N	I	H	G	T	N	K	H	W	L	I	R	Q	A	K	GL6SHUMAN
G	K	M	N	D	V	H	I	S	F	T	D	L	L	H	R	R	R	L	Q	T	L	Q	S	V	D	E	G	I	E	R	L	F	N	L	R	E	L	N	Q	L	W	N	T	CELK09C4	
G	P	M	L	P	I	H	M	E	F	T	N	I	L	Q	R	K	R	L	Q	T	L	M	S	V	D	D	S	V	E	R	L	N	M	L	V	E	T	G	E	L	E	N	T	ts99	
T	P	M	T	N	S	S	I	Q	F	L	D	N	A	F	R	K	R	W	Q	T	L	L	S	V	D	D	L	V	E	K	L	V	K	R	L	E	F	T	G	E	L	N	N	T	GL6SHUMAN
Y	A	I	Y	T	S	D	H	G	Y	H	L	G	Q	F	G	L	L	K	G	K	N	M	P	Y	E	F	D	I	R	V	P	F	F	M	R	G	P	G	I	P	R	CELK09C4			
Y	I	I	Y	T	A	D	H	G	Y	H	I	G	Q	F	G	L	V	K	G	K	S	M	P	Y	D	F	D	I	R	V	P	F	F	I	R	G	P	S	V	E	P	ts99			
Y	I	F	Y	T	S	D	N	G	Y	H	T	G	Q	F	S	L	P	I	D	K	R	Q	L	Y	E	F	D	I	K	V	P	L	V	R	G	P	G	I	K	P	GL6SHUMAN				

FIG. 4



**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification</b> <sup>6</sup> : A61K 38/00, 37/00, 31/33, 39/395, G01N 33/53, C07K 2/00, 14/475, 14/705, 4/71, 16/22, 16/28	<b>A3</b>	<b>(11) International Publication Number:</b> <b>WO 00/06086</b> <b>(43) International Publication Date:</b> 10 February 2000 (10.02.00)
<b>(21) International Application Number:</b> PCT/US99/17178 <b>(22) International Filing Date:</b> 29 July 1999 (29.07.99)  <b>(30) Priority Data:</b> 09/127,651 31 July 1998 (31.07.98) US  <b>(63) Related by Continuation (CON) or Continuation-in-Part (CIP) to Earlier Application</b> US 09/127,651 (CIP) Filed on 31 July 1998 (31.07.98)  <b>(71) Applicant (for all designated States except US):</b> THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK [US/US]; West 116th Street and Broadway, New York, NY 10027 (US).  <b>(72) Inventors; and</b> <b>(75) Inventors/Applicants (for US only):</b> WINCHESTER, Robert, J. [US/US]; 60 East End Avenue, New York, NY 10028 (US). SEKI, Tetsunori [JP/US]; Apartment #411, 595 Main Street, Roosevelt Island, NY 10044 (US). GULKO, Percio, Saltz [BR/US]; Apartment #6H, 3220 Netherland Avenue, Riverdale, NY 10463 (US).		<b>(74) Agent:</b> WHITE, John, P.; Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY 10036 (US).  <b>(81) Designated States:</b> AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).  <b>Published</b> <i>With international search report.</i>  <b>(88) Date of publication of the international search report:</b> 28 September 2000 (28.09.00)
<b>(54) Title:</b> USE OF INHIBITORS OF THE ACTIVATION OF CXCR4 RECEPTOR BY SDF-1 IN TREATING RHEUMATOID ARTHRITIS  <b>(57) Abstract</b>  This invention provides a method for treating rheumatoid arthritis or other forms of inflammatory arthritis which comprises administering to a subject an amount of an agent effective to inhibit the activation of the CXCR4 receptor by SDF-1. This invention further provides a composition for treating rheumatoid arthritis comprising an effective amount of an agent capable of inhibiting the activation of the CXCR4 receptor by SDF-1 and a pharmaceutically acceptable carrier. This invention also provides a method for determining whether an agent is capable of inhibiting the activation of the CXCR4 receptor by SDF-1 comprising: (a) contacting cells expressing the CXCR4 receptor in the presence of SDF-1 with the agent under condition permitting activation of the CXCR4 receptor by SDF-1 if the agent is absent; and (b) determining whether the amount of activation of the CXCR4 receptor by SDF-1 is decreased in the presence of the agent relative to the amount of activation in its absence, such a decrease indicating that the agent is capable of inhibiting the activation of the CXCR4 receptor by SDF-1. Finally, this invention provides agents identified by such a method.		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/17178

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :Please See Extra Sheet.

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 424/133.1, 143.1, 145.1, 144.1, 153.1; 435/7.2; 514/2, 183, 825, 885; 530/300, 387.3, 388.22, 388.23, 388.7, 395; 540/474

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

MEDLINE, BIOSIS, EMBASE, CHEM AB, WEST 1.2; search terms: author names, SDF, CXCR4, AMD3100, bicyclam, arthritis, inflammatory, antibody

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,563,048 A (HONJO et al.) 08 October 1996, see entire document.	1-17
X ----- Y	SCHOLS et al. Bicyclams, a Class of Potent Anti-HIV Agents, are Targeted at the HIV Coreceptor Fusin/CXCR-4. Antiviral Research. 1997, Vol. 35, pages 147-156, see entire document.	7,11,12,16,1 ----- 1-6,8-10,13-15

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*B* earlier document published on or after the international filing date	*Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*A* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

02 SEPTEMBER 1999

Date of mailing of the international search report

21 OCT 1999

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

RON SCHWADRON

Telephone No. (703) 308-0196

JOYCE BRIDGERS  
PARALEGAL SPECIALIST  
CHEMICAL MATRICES

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/17178

A. CLASSIFICATION OF SUBJECT MATTER:

IPC (6):

A61K 38/00, 37/00, 31/33, 39/395; G01N 33/53; C07K 2/00, 14/475, 14/705, 4/71, 16/22, 16/28

A. CLASSIFICATION OF SUBJECT MATTER:

US CL :

424/133.1, 143.1, 145.1, 144.1, 153.1; 435/7.2; 514/2, 183, 825, 885; 530/300, 387.3, 388.22, 388.23, 388.7, 395;  
540/474